mosapride

Mosapride is a gastroprokinetic agent and small molecule drug that acts primarily as a selective agonist of the serotonin 5-hydroxytryptamine type 4 (5-HT4) receptor in the enteric nervous system. By stimulating these receptors, mosapride increases the release of acetylcholine, thereby enhancing gastrointestinal motility and accelerating gastric emptying[1][2][3][6]. Its major active metabolite (M1) also acts as an antagonist at serotonin 5-HT3 receptors[3][6]. Mosapride is used for the treatment of various gastrointestinal disorders associated with reduced motility, including gastritis, gastroesophageal reflux disease (GERD), functional dyspepsia, irritable bowel syndrome (IBS), heartburn, nausea, vomiting due to chronic gastritis, acid reflux disease and indigestion[3][4][5]. In addition to its prokinetic effects, it may exert anti-inflammatory actions on the GI tract and promote neurogenesis in enteric neurons[3].

Brand names

Mosart

Other names

mosapridemosapride citrate4-amino-5-chloro-2-ethoxy-N-((4-(4-fluorobenzyl)-2-morpholinyl)methyl)benzamide